J&J, Actelion to reach agreement on price

Johnson & Johnson is reportedly close to reach an agreement with Actelion on a price to acquire the Swiss biotechnology company. Actelion currently has a market value of $25bn and the US giant has reportedly valued it at approximately $28bn. In addition, talks are now said to have focused on the structure of the new entity, which will have Actelion’s rich pipeline as its asset. (Source Bloomberg)